Sarcoidosis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
ACE I/D genotype influences longitudinal serum ACE activity in sarcoidosis.
Leffers Henrik Christian Bidstrup et al. — Gene (5 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41871628/
- 2.
The double threat: imaging manifestations of thoracic sarcoidosis with miliary nodules and myocardial involvement with radiologic-pathologic correlation.
Kataria Shweta et al. — The international journal of cardiovascular imaging (4 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41933232/
- 3.
Double-QRS Complex Revealing a Multilayer Intramural-Epicardial Ventricular Tachycardia Circuit in Cardiac Sarcoidosis.
Takahashi Masao et al. — JACC. Case reports (3 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41931096/
- 4.
[Bone sarcoidosis: an underrecognized manifestation of a multisystemic disease].
Beniada Camille et al. — Revue medicale suisse (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41923513/
- 5.
Remission in sarcoid uveitis: identification of predictive factors.
Siriphanh Amy et al. — The British journal of ophthalmology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41922096/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT03486873
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sarcoidosis
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
Most Recent Research
PURPOSE: Serum angiotensin-converting enzyme (sACE) is widely used as a biomarker in sarcoidosis, yet interpretation is complicated by genetic variability. We investigated whether ACE insertion/deletion (I/D) genotype influences longitudinal sACE activity and its relationship to clinical manifestations and treatment response. METHODS: Forty-six patients with confirmed sarcoidosis and available ACE genotype data were included. sACE activity was measured longitudinally and normalized to the assay-specific upper limit of normal (sACE index). Linear mixed modeling assessed genotype-specific trajectories over time. Organ involvement and treatment response were compared across genotypes. RESULTS: Genotype distribution was DD (35%), ID (41%), and II (24%). Baseline sACE index showed a descending numerical trend across genotypes but did not differ significantly. Longitudinal modeling demonstrated a significantly steeper decline in sACE index in DD compared with ID and II genotypes (p < 0.001 for interaction). Organ involvement and treatment response did not differ across genotypes. CONCLUSION: ACE I/D genotype influences longitudinal serum ACE activity in sarcoidosis. Genotype-informed interpretation may improve biomarker-based monitoring.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.